Half-life–extended bispecific T-cell engager (BiTE) antibody biologic that binds BCMA on malignant plasma cells and CD3 on T cells to redirect and activate cytotoxic T cells against BCMA-positive multiple myeloma cells; administered subcutaneously (± IV).
Half-life–extended bispecific T-cell engager antibody that binds BCMA on malignant plasma cells and CD3 on T cells, creating an immune synapse to redirect and activate cytotoxic T cells, leading to targeted lysis of BCMA-positive myeloma cells.
AMG 701 bridges CD3 on T cells to BCMA on target cells, forming an immune synapse and activating T cells to kill BCMA+ cells via perforin/granzyme-mediated cytolysis.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
ATLG contains antibodies that bind CD2 on T cells, triggering complement-dependent lysis and Fc-mediated ADCC; crosslinking can also induce apoptosis, depleting CD2+ cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
ATLG antibodies bind CD3ε on T cells and deplete them via complement-dependent cytotoxicity and Fc-mediated ADCC; binding can also induce apoptosis.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
ATLG antibodies bind TCRα/TCR complex on T cells and induce complement-dependent cytotoxicity and Fc-mediated ADCC, leading to lysis and apoptosis of the T cells.
Polyclonal IgG biologic immunosuppressant targeting T lymphocytes, administered pre-transplant to prevent GVHD. Depletes and modulates T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; inhibits T-cell activation/proliferation and trafficking; may reduce antigen-presenting cell activity and inflammatory cytokine signaling.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, ADCC, and apoptosis; also suppresses T-cell activation/proliferation and trafficking and dampens APC activity and inflammatory cytokine signaling to prevent GVHD.
ATLG antibodies bind TCRβ on T cells, opsonizing them for complement-dependent lysis and Fc-mediated ADCC, and can also induce apoptosis, leading to direct T-cell depletion.